Bangkok, Thailand (PRWEB) August 18, 2006
Don Margolis, Founder of TheraVitae, the producer of VesCell Adult Stem Cell Therapy for Heart Disease wished legendary Hawaiian crooner Don Ho a happy birthday today from his home in Bangkok, Thailand.
“A friend sent me a recent story published in the Honolulu Advertiser about Don Ho. When I met him at Bangkok Heart Hospital last year, we hit it off right away. I am delighted to see that Don’s recovery has progressed so well. I just wanted to take this opportunity to wish Don a happy 76th birthday -- and many more,” said Margolis.
TheraVitae is one of the world’s leading stem cell therapy companies, focused on using the patient's own (autologous) adult stem cells to treat a variety of disorders, especially cardiovascular diseases. Nominated by the World Economic Forum as a Technology Pioneer for 2006, the company conducted a clinical trial in Bangkok, Thailand that led to the approval of its first commercial therapy for "no option" heart patients, VesCell. Over 130 patients suffering from very severe angina pectoris or heart failure have been successfully treated with VesCell by either administration of the cells through the heart arteries, or by direct injection into the heart muscle.
On April 12, 2006, the company announced the enrollment of its first patient in a clinical trial to study the safety and efficacy of the administration of autologous adult stem cells to patients suffering from severe Peripheral Artery Disease (PAD), a deficiency of blood supply to the lower limbs.
About Heart Disease
Approximately 13 million Americans, or 7% of the population, have one or more types of heart disease, a disease which caused one of every five deaths in the US in 2003 and which is the single largest killer of Americans. An individual is more than 10 times more likely to die of heart disease than in an accident and more than 30 times as likely to die of heart disease than of AIDS. Approximately every 26 seconds an American will suffer a coronary event, and about every minute someone will die from one. The resulting costs for the treatment of heart disease in the US are enormous, estimated to reach $258.5 billion in 2006.
PAD is a form of atherosclerosis—the hardening and narrowing of the arteries, caused by the gradual buildup of fatty deposits and other substances. PAD affects 8 million to 12 million people in the US, afflicting men and women equally. By age 70, almost 20 percent of the population is affected. Estimates suggest that approximately 1% of adults over 50 years of age suffer from severe PAD, which translates to an estimated population of between 1.5–2 million patients in Europe and the US. Such patients require prompt surgical attention. Otherwise they are likely to require limb amputation. It is estimated that 150,000 amputations are carried out in the US and Europe annually after failure of such surgery.
For Additional Information on Stem Cell Therapy:
36/72 PS Tower, 21/Fl., Sukhumvit 21, Klongtoey Nua, Bangkok 10110
Phone: +662-664-4290/3 Fax: +662-664-42-89
7 Pinhas Sapir Street P.O. Box 4049, Ness Ziona 74140, Israel
Phone: +972-8-9409170 Fax: +972-8-9409167
TheraVitae Inc. - North America
1 Dundas Street, Suite 2500
Toronto, ON, Canada, M5G 1Z3
Phone: 416-593-3773 Fax: 416-204-1939
# # #